Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Treasury Shares (2020 - 2025)

10x Genomics (TXG) has disclosed Treasury Shares for 6 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 20.53% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 20.53% year-over-year, with the annual reading at $7.8 million for FY2025, 20.53% up from the prior year.
  • Treasury Shares hit $7.8 million in Q4 2025 for 10x Genomics, down from $8.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.2 million in Q2 2025 to a low of $985386.0 in Q1 2021.
  • Historically, Treasury Shares has averaged $5.1 million across 5 years, with a median of $5.8 million in 2022.
  • Biggest five-year swings in Treasury Shares: skyrocketed 1591.53% in 2021 and later decreased 8.6% in 2023.
  • Year by year, Treasury Shares stood at $1.3 million in 2021, then skyrocketed by 349.55% to $5.8 million in 2022, then fell by 8.6% to $5.3 million in 2023, then grew by 21.73% to $6.5 million in 2024, then rose by 20.53% to $7.8 million in 2025.
  • Business Quant data shows Treasury Shares for TXG at $7.8 million in Q4 2025, $8.5 million in Q3 2025, and $9.2 million in Q2 2025.